Search

Machine Learning Layer Boosts 14-Gene Oral Cancer Test Across Diverse

A rapid qMIDS-like molecular test for oral cancer is enhanced with machine learning, improving diagnostic performance across UK, India, and China cohorts; the study uses late fusion of MI with gene-expression data and validates multiple classifiers with rigorous cross-validation.

Which AI Models Read DNA? AlphaGenome, Evo 2, and Borzoi at a Glance

Translated title. Original: Welche KI-Modelle lesen DNA? AlphaGenome, Evo 2 und Borzoi im Überblick

The article compares seven DNA models by their tasks, origins, input lengths, and access options. It explains how they read, predict, or generate genetic sequences and notes that none replaces clinical testing.

AlphaGenome 2 unveiled: Genomics AI needs a clear statement about its limitations – 10-minute AI Brief

Translated title. Original: AlphaGenome 2 vorgestellt: Genom-KI braucht eine klare Aussage über ihre Grenzen – 10min KI-Brief

AlphaGenome 2 predicts how DNA changes may affect molecular processes, but it has not been validated for clinical or diagnostic use. The article advises businesses to check the model’s limits, intended use, data requirements, and evidence before making claims or adopting it.

AlphaGenome 2: DeepMind’s AI that predicts how every DNA mutation changes every cell

Translated title. Original: AlphaGenome 2: la IA de DeepMind que predice cómo cada mutación del ADN cambia cada célula

AlphaGenome 2 predicts how DNA variants may affect gene activity in different cell types, helping researchers prioritize experiments. Its claims still need independent validation, and gaps in training data may lead to biased results.

An AI deciphers the language that cells use to communicate with each other

Translated title. Original: Una IA descifra el lenguaje que utilizan las células para comunicarse entre sí

A study shows that signaling pathways leave stable, cell-type-independent fingerprints in gene activity, enabling reconstruction of signaling histories in single cells; powered by the IRIS AI system and led by Nicholas Hutchins, with findings published in Nature Methods.

Google DeepMind Releases AlphaGenome 2 for Cell-Type-Specifi - Global 1 News

AlphaGenome 2 predicts gene activity and other DNA effects across cell types, with DeepMind reporting gains over its predecessor on several benchmarks. It is currently API-only, and planned weight access is limited to non-commercial use, which may restrict independent hosting and commercial services.

Google DeepMind Releases AlphaGenome 2 for Cell-Type-Specific Variant Effects - MarkTechPost

Google DeepMind’s AlphaGenome 2 predicts genetic variant effects for specific cell types from 1 Mb DNA sequences. It outperformed earlier models on several reported single-cell benchmarks and is available through a hosted API for non-commercial research.

Aignostics Launches AI Software to Assess Tissue for Molecular Testing

Aignostics launches RUO and HETA Clinical AI tools to quantify tumor content and tissue quality in digital slides, aiming to reduce molecular testing failures and speed workflows. The suite, built on the HETA platform, targets tumor presence, mitotic counts, and cellularity, with plans for broader integration and additional products.

A new atlas of tissues will help artificial intelligence understand cancer - MediTutor

Translated title. Original: Un nuovo atlante dei tessuti aiuterà l’intelligenza artificiale a comprendere il cancro - MediTutor

Researchers at EPFL have created Spora, the world's largest open-access proteomics tissue atlas, compiling 13,546 images from 5,477 patients across 14 tissues and five imaging methods. The resource harmonizes data, links clinical and cellular context, and supports AI evaluation, with immediate focus on cancer and potential expansion to other diseases.

Machine learning sharpens leukemia diagnosis but waits on rigorous

A literature review on AML shows bioinformatics and ML can aid diagnosis, prognosis, and treatment planning by integrating multi-omics data, but clinical adoption is hindered by methodological issues and a need for prospective validation and external testing.